drugset / Trial / NCT04194684
Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open, multi-center clinical study of nab-paclitaxel as the therapy ER+/HER2- recurrent metastatic breast cancer。
Timeline
- Start
- 2019-12-28
- Primary completion
- 2022-12-28
- Completion
- 2023-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |